trial summary · NCT07825064
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
A Phase II, Single Arm, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Have Received a Prior BCMA-Targeting CAR T-Cell Therapy
Trial record from the TrialBase DB dataset, status RECRUITING, condition Multiple Myeloma, sponsored by Hoffmann-La Roche. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) in patients with multiple myeloma (MM) who have received one to four prior lines of therapy and have been exposed to an anti-cluster of differentiation 38 (CD38) antibody, lenalidomide, a proteasome inhibitor (PI) and a B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy.
Source record: https://clinicaltrials.gov/study/NCT07825064
Facts
| registry id | NCT07825064 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Multiple Myeloma |
| sponsor | Hoffmann-La Roche |
| sponsor class | INDUSTRY |
| enrollment | 45 |
| start date | 2026-10-30 |
| primary completion | 2029-04-13 |
| completion | 2031-01-19 |
| results posted | not reported |
Conditions
- Multiple Myeloma
Interventions
- Cevostamab
- Pomalidomide
- Dexamethasone
- Tocilizumab
Countries
- Germany
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.